

CMS Issues Final Negotiated Prices for Initial Price Applicability Year 2026

- On August 15, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the Final Negotiated Prices for Initial Price Applicability Year 2026 under the Inflation Reduction Act (IRA).
- The drugs selected for this negotiation are Januvia, Fiasp, Farxiga, Enbrel, Jardiance, Stelara, Xarelto, Eliquis, Entresto, and Embruvica. The new Maximum Fair Prices (MFP) will go into effect on January 1, 2026, with discounts ranging from 38 to 79 percent. In 2023, these selected drugs accounted for \$56.2 billion in total Part D gross covered prescription drug costs. According to CMS, this will result in an estimated \$1.5 billion in savings when the MFP goes into effect in 2026 in addition to other costs savings from the IRA.
- CMS will select 15 additional Part D drugs for 2027, 15 additional Part B or Part D drugs for 2028, and up to 20 more Part B or Part D drugs for each year after that.
- The Office of the Assistant Secretary for Planning and Evaluation (ASPE) also released new data showing historic pricing trends for the 10 drugs selected.
- CMS will publish an explanation of the agreed-upon negotiated prices by March 2025.

More on This Topic:

- [Fact Sheet](#)
- [Press Release](#)
- [CMS Infographic](#)
- [ASPE Issue Brief](#)

For questions, please reach out to [Vicky Jucelin](#).